16 September 2026 note archive · Item
Insulin detemir (Levemir): review notes
These archived notes document the scope reviewed on 16 September, including source-access limits. They do not cover later changes or newly added records. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Insulin detemir (Levemir)
Scope and findings: Added in the second discovery pass. An established basal insulin being phased out. Australian and Dutch presentations are scheduled to end in December2026; the US brand is already on FDA’s discontinued list. Remaining stock must be checked locally. Numerical claims are tied to the cited product specifications or named study, and editorial scores do not represent measured comparative performance.
Primary sources checked:
- Levemir prescribing information
- TGA current insulin supply changes
- FDA discontinued biologic product list, April2026
- Novo Nordisk Netherlands portfolio phase-out dates
Limits: Scope is the specific claims documented in the new record. Local stock, payer rules, every hardware variant and unreported head-to-head outcomes are not verified. Regulatory status, manufacturer marketing and clinical performance are distinct.